Drug Interactions With New Synthetic Opioids

Area of Science:

• Pharmacology
• Toxicology
• Public Health

Background:

• New psychoactive substances (NPS), including fentanyl analogs and other new synthetic opioids (NSO), are increasingly prevalent on the illicit drug market.
• These substances, often misrepresented as heroin, act as potent μ-opioid receptor agonists, leading to widespread euphoria and addiction.
• The opioid crisis, particularly in the United States, is exacerbated by the high consumption of these NSO, often in poly-intoxication cases.

Purpose of the Study:

• To review the most frequent drug-drug interactions involving opioid NPS.
• To identify co-ingested substances in reported poly-intoxication cases, including other drugs of abuse and medications.
• To inform healthcare professionals about the risks associated with designer opioids.

Main Methods:

• Literature review of reported poly-intoxication cases involving opioid NPS.
• Analysis of co-ingested substances, including antidepressants, antihistamines, antipsychotics, benzodiazepines, analgesics, anesthetics, psychostimulants, other opioids, alcohol, and illicit drugs.
• Examination of pharmacokinetic and pharmacodynamic interaction mechanisms.

Main Results:

• Fentanyl analogs are significantly more potent than fentanyl and morphine, with some exhibiting longer durations of action.
• Commonly involved co-ingested substances include antidepressants, benzodiazepines, and other central nervous system depressants.
• Interactions can arise from both pharmacokinetic and pharmacodynamic mechanisms, increasing the risk of severe intoxication.

Conclusions:

• Opioid NPS present a significant public health challenge due to their potency and potential for life-threatening drug-drug interactions.
• Naloxone may be required in higher doses for opioid NPS intoxications.
• Healthcare providers must be aware of these interactions to prevent further cases of intoxication and improve patient safety.